Brian VanderBeek of the Perelman School of Medicine is highlighted for leading a study on the safety of a costly eye drug in comparison to its cheaper alternative.
http://www.philly.com/philly/health/20150814_Penn_study__Costly_eye_drug_no_safer_than_alternative.html Philadelphia Inquirer